Deals of the day-Mergers and acquisitions

(Adds Banco, Bulb, PDVSA; updates Suncor, HSBC, ALD) Nov 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2055 GMT on Tuesday: ** Banco BPM has picked its top

What to Watch in the Day Ahead - Wednesday, November 30

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users

BRIEF-Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer

Nov 29 (Reuters) - Immutep Ltd: * IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-

Deals of the day-Mergers and acquisitions

(Adds Banco, Bulb, PDVSA; updates Suncor, HSBC, ALD) Nov 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2055 GMT on Tuesday: ** Banco BPM has picked its top

Deals of the day-Mergers and acquisitions

(Adds Banco, Bulb, PDVSA; updates Suncor, HSBC, ALD) Nov 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2055 GMT on Tuesday: ** Banco BPM has picked its top

UK STOCKS-Factors to watch on Nov 30

Nov 30 (Reuters) - Britain's FTSE 100 index is seen opening higher on Wednesday, with futures up 0.37%. * RIO TINTO: Rio Tinto plans to invest a further $600 million in renewable energy assets in the

BRIEF-Little Green Pharma Says Received Ethics Approval For Cbd Phase Iii Clinical Trial

Nov 30 (Reuters) - Little Green Pharma Ltd: * RECEIVED ETHICS APPROVAL FOR CBD PHASE III CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Mayne Pharma Says Return To Positive EBITDA Expected In FY24

Nov 30 (Reuters) - Mayne Pharma Group Ltd: * FOCUSED ON DRIVING IMPROVED PROFITABILITY AND CASH FLOW WITH RETURN TO POSITIVE EBITDA EXPECTED IN FY24 Source text for Eikon: Further company coverage:

Australian shares fall; focus on Powell's speech, China data

Nov 30 (Reuters) - Australian shares slipped on Wednesday, with energy stocks leading the declines, as cautious investors eyed key data from China and U.S. Federal Reserve Chair's speech later in the

BRIEF-Little Green Pharma Says HY Revenue From Ordinary Activities Up 25%

Nov 30 (Reuters) - Little Green Pharma Ltd: * HY REVENUE FROM ORDINARY ACTIVITIES UP 25% TO A$9.2 MILLION * HY LOSS AFTER TAX FROM CONTINUING OPERATIONS A$7.5 MILLION VERSUS LOSS OF A$8.6 MILLION